Presurgical Smoking Cessation Intervention for Cancer Patients: The Resolve Study
Smoking cessation offers an important way for newly diagnosed cancer patients to take an
active role in their treatment and recovery. Quitting tobacco use decreases cancer patients'
risk of disease recurrence and development of second primary cancers. In addition,
preoperative tobacco cessation may reduce the likelihood of perioperative pulmonary,
cardiovascular, and wound healing complications. Due to increased awareness of the health
hazards of tobacco use, rates of cessation after cancer diagnosis are high. However, 35% to
69% of patients continue to use tobacco and this is largely due to strong barriers to
quitting (low-self efficacy, psychological distress) rather than lack of positive intentions
to quit. Previous attempts to increase smoking cessation among the medically ill have
provided intervention either during or after hospitalization.
We propose that the period immediately prior to hospitalization and surgery represents a
unique window of opportunity, or "teachable moment," for smoking cessation that could take
full advantage of patients' enhanced health awareness and quitting motivation, strong
physician quitting advice, and patients' heightened desire to take an active role in their
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
efficacy of a presurgical smoking cessation intervention that adds scheduled reduced smoking, a highly effective behavioral treatment in non-medically ill tobacco users, to enhanced usual care, i.e., hospital counseling and nicotine replacement therapy.
will be measured at hospital admission, and 3 and 6 months post-hospital admission.
Jamie Ostroff, PhD
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
|Memorial Sloan Kettering Cancer Center||New York, New York 10021|